Ascend Therapeutics

Sequella Inc. is a clinical-stage pharmaceutical company based in Rockville, MD, focused on developing innovative antibiotics to combat drug-resistant bacterial, fungal, and parasitic infections. Their product pipeline addresses significant global health threats, particularly tuberculosis and its multidrug-resistant forms, which impact billions of people worldwide. With two drug candidates having completed phase 2 clinical trials and additional candidates in preclinical development, Sequella aims to tackle various infectious diseases, including Helicobacter pylori infections and Clostridium difficile. Their research also explores treatments for non-tuberculous mycobacterial infections and parasitic diseases, demonstrating a commitment to addressing critical health challenges globally. Generated from the website

Incorporated in 1989, Otsuka America Pharmaceutical is a health care company that commercializes its products throughout North America. It offers products under the ABILIFY Tablets1 and PLETAL Tablets2 brands. The company works in collaboration with Bristol-Myers Squibb, which co-develops and co-promotes ABILIFY. Otsuka America Pharmaceutical has also merged with Meretek Diagnostics to form the Meretek Diagnostics Group under the Medical Device Division of OAPI. It focuses on neuroscience, cardiovascular, oncologic and gastrointestinal therapeutic treatments. The company operates Otsuka Maryland Research Institute, which was established as a wholly-owned subsidiary of OAPI to research and develop a variety of health care products. Otsuka America Pharmaceutical is a part of Otsuka Pharmaceutical Group.